Trial Number
353-23
Conditions
Headache, Migraine & Headache
Participant Age Range
6 years to 17 years
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – The REBUILD-1 Study”
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo (an inactive substance) in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.